2-溴-1-环戊烯硼酸 | 612833-43-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 硼酸衍生物
• 中文名称: 2-溴-1-环戊烯硼酸
• 英文名称: 2-bromo-1-cyclopenteneboronic acid
• 英文别名: 2-bromocyclopent-1-enylboronic acid；(2-Bromocyclopent-1-en-1-yl)boronic acid；(2-bromocyclopenten-1-yl)boronic acid
• CAS: 612833-43-9
• 化学式: C₅H₈BBrO₂
• 分子量: 190.832
• InChiKey: GGQMVPOUNAYCRQ-UHFFFAOYSA-N

物化性质

• 沸点：
  283.5±50.0 °C(Predicted)
• 密度：
  1.63±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.83
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-溴-1-环戊烯硼酸 在 四(三苯基膦)钯 作用下， 以 乙二醇二甲醚 、 乙醇 、 水 、 甲苯 为溶剂， 生成
  参考文献：
  名称：

  The discovery of 6-[2-(5-chloro-2-{[(2,4-difluorophenyl)methyl]oxy}phenyl)-1-cyclopenten-1-yl]-2-pyridinecarboxylic acid, GW848687X, a potent and selective prostaglandin EP1 receptor antagonist for the treatment of inflammatory pain

  摘要：

  The discovery of a series of selective EP1 receptor antagonists based on a 1,2-diaryleyclopentene template is described. After defining the structural requirements for EP1 potency and selectivity, heterocyclic rings were incorporated to reduce logD and improve in vitro pharmacokinetic properties. The 2,6-substituted pyridines and pyridazines gave an appropriate balance of potency, in vivo pharmacokinetic properties and a low potential for inhibiting a range of CYP450 enzymes. From this series, GW848687X was shown to have an excellent profile in models of inflammatory pain and was selected as a development candidate. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.10.041
• 作为产物：
  描述：

  1,2-二溴环戊烯 在 正丁基锂 、 硼酸三异丙酯 、 盐酸 、 水 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 0.92h， 以26%的产率得到2-溴-1-环戊烯硼酸
  参考文献：
  名称：

  [EN] (2-((2-ALKOXY) -PHENYL) -CYCLOPENT-1-ENYL) AROMATIC CARBO AND HETEROCYCLIC ACID AND DERIVATIVES
  [FR] ACIDE (2-((2-ALCOXY) -PHENYL) -CYCLOPENT-1-ENYL) AROMATIQUE CARBOCYCLIQUE AND HETEROCYCLIQUE ET SES DERIVES

  摘要：

  式(I)或其药学上可接受的衍生物的化合物：其中A、R1、R2、Rx、R8、R9和n如规范中所定义，一种制备这种化合物的方法，包括这种化合物的药物组合物以及这种化合物在医学上的用途。

  公开号：

  WO2003084917A1

文献信息

• Cyclopentene compounds
  申请人：Giblin Gerard Martin Paul

  公开号：US20090227591A1

  公开（公告）日：2009-09-10

  Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein A, B, Z, R 1 , R 2a , R 2b , R 8 , R 9 , and R x are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.

  化合物的式子（I）或其药学上可接受的衍生物： 其中A、B、Z、R1、R2a、R2b、R8、R9和Rx如规范中所定义，制备这种化合物的工艺，包含这种化合物的制药组合物以及这种化合物在医学上的用途。
• [EN] (2-((2-ALKOXY) -PHENYL) -CYCLOPENT-1-ENYL) AROMATIC CARBO AND HETEROCYCLIC ACID AND DERIVATIVES<br/>[FR] ACIDE (2-((2-ALCOXY) -PHENYL) -CYCLOPENT-1-ENYL) AROMATIQUE CARBOCYCLIQUE AND HETEROCYCLIQUE ET SES DERIVES
  申请人：GLAXO GROUP LTD

  公开号：WO2003084917A1

  公开（公告）日：2003-10-16

  Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: (I) wherein A, R1 , R2 , Rx , R8 , R9 and n are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.

  式(I)或其药学上可接受的衍生物的化合物：其中A、R1、R2、Rx、R8、R9和n如规范中所定义，一种制备这种化合物的方法，包括这种化合物的药物组合物以及这种化合物在医学上的用途。
• The discovery of 6-[2-(5-chloro-2-{[(2,4-difluorophenyl)methyl]oxy}phenyl)-1-cyclopenten-1-yl]-2-pyridinecarboxylic acid, GW848687X, a potent and selective prostaglandin EP1 receptor antagonist for the treatment of inflammatory pain
  作者：Gerard M.P. Giblin、Rino A. Bit、Susan H. Brown、Hélène M. Chaignot、Anita Chowdhury、Iain P. Chessell、Nicholas M. Clayton、Tanya Coleman、Adrian Hall、Beverley Hammond、David N. Hurst、Anton D. Michel、Alan Naylor、Riccardo Novelli、Tiziana Scoccitti、David Spalding、Sac P. Tang、Alex W. Wilson、Rich Wilson

  DOI：10.1016/j.bmcl.2006.10.041

  日期：2007.1

  The discovery of a series of selective EP1 receptor antagonists based on a 1,2-diaryleyclopentene template is described. After defining the structural requirements for EP1 potency and selectivity, heterocyclic rings were incorporated to reduce logD and improve in vitro pharmacokinetic properties. The 2,6-substituted pyridines and pyridazines gave an appropriate balance of potency, in vivo pharmacokinetic properties and a low potential for inhibiting a range of CYP450 enzymes. From this series, GW848687X was shown to have an excellent profile in models of inflammatory pain and was selected as a development candidate. (c) 2006 Elsevier Ltd. All rights reserved.